BRIEF-Heat Biologics substantially reduces debt and reports proceeds of approximately $2.8 million
Oct 7 Heat Biologics Inc
* Heat Biologics substantially reduces debt and reports proceeds of approximately $2.8 million year to-date from the exercise of warrants
* Says that it has paid down $1.5 million on its commercial loan following recent exercise of warrants Source text for Eikon: Further company coverage:
CORRECTED-U.S. FDA outlines plan to speed rare disease drug designation
WASHINGTON, June 29 The U.S. Food and Drug Administration plans to reorganize its drug review staff and create a SWAT team to eliminate a backlog of requests for rare disease drug designation, it said on Thursday.